natgillin/translations-raw huggingface dataset:
is independently chosen from naphthyl, naphthyloxy, indanyl, (4- to 7-membered heterocycloalkyl)C0-C4alkyl containing 1 or 2 heteroatoms chosen from N, O, and S, and bicyclic heterocycle containing 1, 2, or 3 heteroatoms independently chosen from N, O, and S, and containing 4- to 7-ring atoms in each ring; each of which R35 is unsubstituted or substituted with one or more substituents independently chosen from halogen, hydroxyl, nitro, cyano, C1-C6alkyl, C2-C6alkenyl, C2-C6alkanoyl, C1-C6alkoxy, (mono- and di-C1-C6alkylamino)C0-C4alkyl, C1-C6alkylester, —C0-C4alkyl(C3-C7cycloalkyl), —SO2R9, C1-C2haloalkyl, and C1-C2haloalkoxy; and 
je nezavisno odabrana od naftil, naftiloksi, indanil, (heterocikloalkil grupa sa 4 do 7 članova)C0-C4alkil grupe koja sadrži 1 ili 2 heteroatoma koji su odabrani od N, O, i S, i biciklične heterociklične grupe koja sadrži 1, 2, ili 3 heteroatoma koji su nezavisno odabrani od N, O, i S, i koja sadrži 4 do 7 atoma prstena u svakom prstenu; pri čemu je svaka od R35 nesupstituirana ili supstituirana sa jednim ili više supstituenata koji su nezavisno odabrani od halogena, hidroksilne, nitro, cijano, C1-C6alkil, C2-C6alkenil, C2-C6alkanoil, C1-C6alkoksi, (mono- i di-C1-C6alkilamino)C0-C4alkil, C1-C6alkilestarske, -C0-C4alkil(C3-C7cikloalkil), -SO2R9, C1-C2haloalkil, i C1-C2haloalkoksi grupe; i
The branch of conduit 14 to nozzle 12 (not shown in FIG. 6C) would operatively connect to fluid outlet 210 . 
Ogranak cjevovoda 14 do mlaznice 12 (nije prikazana na slici 6C) bit će povezan s izlazom 210 fluida.
and the second layer comprises: 
mm a drugi sloj sadrži:
wherein: represents a halogen atom or hydrogen atom; 
– R1 predstavlja atom halogena ili atom vodika;
A pharmaceutical composition comprising an effective amount of at least one compound of formula (I) or pharmacologically acceptable salt thereof according to claim 1, pharmaceutically tolerated excipients and carriers and, where appropriate, further additives and/or other active ingredients. 
Medikament, naznačen time što sadrži djelotvornu količinu najmanje jednog spoja formule (I) i/ili njegove farmakološki prihvatljive soli u skladu s bilo kojim od patentnih zahtjeva 1 do 44, farmaceutski podnošljive pomoćne tvari i podloge i, gdje je to prikladno, dodatne aditive i/ili druge aktivne sastojke.
hetaryl II is a five or six membered heteroaryl group, containing 1 to 3 heteroatoms as defined for hetaryl I above, or is a bicyclic ring system containing 1 to 4 heteroatoms selected from S, O or N, wherein at least one ring is aromatic in nature, and which is selected from the group consisting of 
[image] hetaril II je pet-člana ili šest-člana heteroaril-skupina koja ima od 1 do 3 heteroatoma koji su definirani za gore navedeni hetaril I, ili je to biciklički sustav prstena koji sadrži od 1 do 4 heteroatoma odabranih od S, O ili N, pri čemu je najmanje jedan prsten aromatske prirode, te koja je odabrana iz skupine koju čine: [image] ili
(c3) an antigen-binding site comprising an L chain CDR1, 2, and 3 amino acid sequences of SEQ ID NOs: 144, 145, and 146 (L chain CDR of L248), respectively; 
(c3) mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence L-lanca CDR-područja 1, 213 od SEQ ID NO: 144, 145 odnosno 146 (L-lanac CDR- područja od L248); HR P20180421 T1
In particular, the tumor is selected from: breast cancer, ovarian cancer, bladder cancer, lung cancer, prostate cancer, pancreatic cancer, colon cancer and melanoma and/or cells thereof, for example, breast cancer cells (such as TUBO cells) or Myc-Cap tumor cell line. 
Antitijelo koje blokira B7-H1 za uporabu prema bilo kojem od zahtjeva 1-7, pri čemu je rak odabran od skupine koja se sastoji od raka dojke, raka jajnika, raka mjehura, raka pluća, raka prostate, raka gušterače, raka debelog crijeva i melanoma.
The compound or a pharmaceutically acceptable acid addition salt thereof according to claim 4, wherein R2 is a hydrogen atom, a cyano group, a fluorine atom, a chlorine atom, a methyl group, a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a hydroxymethyl group, an ethyl group, a methoxy group, a fluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, an ethoxy group, a 2-fluoroethoxy group, a 2-propyloxy group, a cyclopropylmethoxy group, a cyclobutylmethoxy group or a (tetrahydro-2H-pyran-4-yl)methoxy group. 
Spoj ili njegova farmaceutski prihvatljiva kisela adicijska sol prema zahtjevu 4, pri čemu R2 je vodikov atom, cijano skupina, fluorov atom, klorov atom, metilna skupina, fluorometilna skupina, difluorometilna skupina, trifluorometilna skupina, hidroksimetilna skupina, etilna skupina, metoksi skupina, fluorometoksi skupina, difluorometoksi skupina, trifluorometoksi skupina, etoksi skupina, 2-fluoroetoksi skupina, 2-propiloksi skupina, ciklopropilmetoksi skupina, ciklobutilmetoksi skupina ili (tetrahidro-2H-piran-4-il)metoksi skupina.
a compound defined by the formula 1 wherein a, b and c respectively denote, independently from each other, a single bond or a double bond, with the proviso that at least one of a, b and c represents a double bond, and with the proviso that if a is single bond and b is double bond, R2 is not H; 
spoj definiran formulom 1 [image], gdje a, b i c, međusobno neovisno, odgovarajuće označuju jednostruku vezu ili dvostruku vezu, uz uvjet da najmanje jedan od a, b i c predstavlja dvostruku vezu, te uz uvjet da ako je a jednostruka veza, a b je dvostruka veza, R2 nije H;
After purification on silica gel (50% hexane/dichloromethane), compound 21 was obtained as a yellow solid. 
Nakon pročišćavanja na silikagelu (50% heksan/diklormetan), dobiva se spoj 21 kao HR P20070430 T3 Žuta krutina.
a gene encoding a heterologous TAP inhibitor polypeptide, wherein the heterologous TAP inhibitor polypeptide is a herpes virus UL49.5 TAP inhibitor polypeptide, a CMV US6 polypeptide, or a BNLF2a polypeptide. 
gen koji kodira heterologni TAP inhibicijski polipeptid, naznačena time što je heterologni TAP inhibicijski polipeptid UL49.5 TAP inhibicijski polipeptid herpes virusa, CMV US6 polipeptid, ili BNLF2a polipeptid.
The milk fat according to any of the preceding claims, which has a saturated fatty acid content less than 35% by weight based on the total fatty acids. 
Mliječna mast prema bilo kojem od prethodnih zahtjeva, naznačena time da je udio zasićene masne kiseline manji od 35% po težini na temelju ukupnih masnih kiselina.
The solid support for cultivation of anchorage-dependent cells may be located either within the bioreactor or within the external column. 
Kruta potpora za uzgoj stanica koje potrebuju pričvršćivanje može biti smještena unutar bioreaktora ili unutar vanjske kolone.
In one aspect, the present invention provides a pharmaceutical preparation comprising spheroids, the spheroids being in the form of a matrix comprising glyceryl monostearate and a polymeric binder in the absence of microcrystalline cellulose. 
Farmaceutski preparat koji sadrži sferoide, pri čemu su sferoidi u obliku matriksa koji sadrži, kao pomoćno sredstvo za sferonizaciju, između 20 1 95% (tež./tež.)
Several patent applications covering the combination of an SSRI and a 5-HT1B antagonist or partial agonist have also been filed (WO 97/28141, WO 96/03400, EP-A-701819 and WO 99/13877). 
Podneseno je nekoliko patentnih prijava koje se bave kombinacijom SSRI i antagonista ili djelomično agonista 5-HT;p (WO 97/28141, WO 96/03400, EP-A-701819 i WO 99/13677).
The method of claim 10, wherein the tissue sample is a blood sample. 
Način prema zahtjevu 10, naznačen time, što uzorak tkiva jest uzorak krvi.
The set of panels as claimed in claim 14, wherein an outer bevel edge of the edge tongue is covered by a part of the decorative layer. 
Komplet ploča prema patentnom zahtjevu 12, naznačen time što je vanjski nakošeni rub rubnog jezičca (22) prekriven dijelom ukrasnog sloja (64).
the compound having the structure of Formula 1 of claim 1; and a pharmaceutically acceptable carrier. The pharmaceutical composition of claim 12, wherein the compound is present in an effective amount to provide a therapeutically effective amount of 6-cyclohexyl-1-hydroxy-4-methylpyudin-2(1H)-one. 
Farmaceutski sastav sadrži: tvar koja ima strukturu formule 1 iz patentnog zahtjeva 1; i farmaceutski prihvatljivi nosač. 13. Farmaceutski sastav iz patentnog zahtjeva 12, pri čemu je tvar prisutna u učinkovitoj količini za omogućavanje 20
The natural oils containing fatty acids in the form of glycerides are usually submitted to standard treatments, as extraction, whitening, deodorization, etc. The polyunsaturated compounds, as—for instance—the above mentioned acids, being in mixture with high quantities of saturated and mono-unsaturated components, are usually isolated from glycerides through hydrolysis or through transesterification and concentrated, for instance by complexing the less unsaturated constituents with urea or by other techniques, chemically modified to derivatives, if requested, and then purified by distillation: however, all these steps damage heavily and at the same time the polyunsaturated compound structure and lead to forming high quantities of by-products with polar structure, which sum themselves to the other preexistent impurities of natural oils or deriving by the environmental polluting agents. 
Prirodna ulja koja sadržavaju masne kiseline u obliku glicerida se obično podvrgavaju standardnim tretmanima, kao što je ekstrakcija, izbjeljivanje, deodorizacija, itd, Polinezasićeni spojevi, kao - na primjer- gore spomenute kiseline, kad su u smjesi s velikim količinama zasićenih i mono-nezasićenih komponenata, se obično izoliraju iz glicerida hidrolizom ili transesterifikacijom 1 koncentriraju, na primjer stvaranjem kompleksa s manje zasićenih sastojaka s ureom ili drugim tehnikama, kemijski modificiraju do derivata, ako je potrebno, i zatim pročišćavaju destilacijom: međutim, svi to koraci teško oštećuju u isto vrijeme polinezasićenu strukturu spoja i dovode do stvaranja velikih količina nusprodukata s polarnom strukturom, što se sve pribraja ostalim već postojećim onečišćenjima prirodnih ulja ili onima koja nastaju od zagađivača u okolišu.
A container for a liquid pharmaceutical composition, the container containing a liquid pharmaceutical composition ready for injection and containing interferon-B as active ingredient, characterised by comprising a closure means coated by an inert fluorinated material and wherein the internal surface of the container is coated by an inert material. 
Spremnik za tekući farmaceutski pripravak, te navedeni spremnik sadrži tekući farmaceutski pripravak spreman za ubrizgavanje, te kao aktivni sastojak sadrži interferon-f5, naznačen time da sadrži sredstva za zatvaranje obložena inertnim fluoriranim materijalom, te time da je unutarnja površina spremnika obložena sa inertnim materijalom.
Method according to any of claims 1 to 29, characterised in that the modified immunoglobulin is conjugated to a lapel selectted from the group consisting of organic molecules, enzyme labels, radioactive labels, coloured, labels, fluorescent label, chromogenic labels, luminescent labels, haptens, digoxigenin, biotin, metal complexes, mentals, colloidal gold and mixtures thereof. 
Postupak u skladu s bilo kojim zahtjevom 1 do 29, naznačen time, da je modificirani imunoglobulin vezan na oznaku izabranu iz skupine koju čine organske molekule, enzimske oznake, radioaktivne oznake, obojene oznake, fluorescentne oznake, kromogene oznake, luminescentne oznake, hapteni, digoksigeni, biotin, metalni kompleksi, metali, koloidno zlato i njihove smjese.
A glucocorticoid contained in a delayed-release dosage form for use according to any one of the previous claims, wherein said patient has or has not been treated previously with an NSAID, a DMARD, a TNFa inhibitor, an analgetic agent, or combinations thereof. 
Glukokortikoid sadržan u obliku doziranja s odgođenim otpuštanjem za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu je navedeni bolesnik bio ili nije bio prethodno liječen oralnim glukokortikoidima s izravnim otpuštanjem, i/ili NSAID-om, DMARD-om, inhibitorom TNFqa, inhibitorom IL-1, inhibitorom IL-6, analgetikom, ili kombinacijama navedenog.
the host cell is capable of producing ethanol, preferably a yeast derived from the group of host cells comprising Saccharomyces cerevisiae, Pichia stipitis, Pachysolen tannophilus and/or 
(ii) stanica domaćina može proizvesti etanol, poželjno kvasac dobiven iz grupe a domaćina koje sadrže kvasac Saccharomyces cerevisiae, kvasac Pichia stipitis, kvasac Pachysolen tannophilus i/ili
Spheroids according to any one of claims 11 to 20 wherein the matrix contains from 50 to 95% w/w glyceryl monostearate. 
Sferoidi prema bilo kom od patentnih zahtjeva 11 do 20 naznačeni time što matriks sadrži od 50 do 95% tež./tež. gliceril monostearata.
The density of suspension cells propagated on such supports is even greater that the density that can be attained in suspension cultures. 
Gustoća stanične suspenzije koja se uzgaja na takovim potporama je čak i veća nego li gustoća koja se može postići u suspenziji bez potpore.
Therefore, a first aspect of the present invention refers to the use of 2-((1-methylpropyl)amino)ethanol as additive in an aqueous suspension containing from 25 to 62 vol. %, based on the total volume of the suspension, of at least one calcium carbonate-comprising material and having a pH of between 8.5 and 11, for increasing the suspension pH by at least 0.3 pH units, wherein the suspension conductivity change is not more than 100 µS/cm per pH unit. "Conductivity" according to the present invention shall mean the electrical conductivity of an aqueous carbonate-comprising material suspension as measured according to the measurement method defined in the examples section herebelow. 
U poraba 2-((1-metilpropil)aminojetanola kao aditiva u vodenoj otopini, sadrži 25 do 62 vol.% na temelju ukupnog volumena otopine, barem jednog materijala s kalcijevim karbonatom i ima pH između 8,5 i 11, za povećanje pH otopine za najmanje 0,3 pH jedinice, pri čemu promjena vodljivosti otopine nije veća od 100 uS/cm po jedinici pH, karakterizirana na način da je navedeni 2-((1-metilpropil)amino)etanol dodan u navedenu otopinu u količini od 500 do 1500 mg, po litri vodene faze navedene otopine.
No. 6,553,987, herein fully incorporated by reference, mentions the use of a specific inhaler with dry powders. 
Posebno, dokument US-A-6553987, spominje upotrebu specifičnih inhalatora sa suhim prahovima.
The formulation of claim 9, wherein said viscogenic agent is a reverse thermosetting gel. 
Formulacija u skladu s patentnim zahtjevom 9, naznačena time što je navedeno viskogeno sredstvo inverzni duromerni gel.
The compound of claim 1, wherein X is hydrobromic acid. 
Spoj prema zahtjevu 1, naznačen time što X je bromovodična kiselina.
a nucleic acid represented by the sequence SEQ ID NO: 3 or a nucleic acid having a sequence identity of at least 85%, particularly 90%, in particular 95% with the sequence SEQ ID NO: 3, coding for the secondary alcohol dehydrogenase of C. beijerinckii, the expression of said nucleic acids being controlled by a single constitutive promoter located upstream of the abovementioned nucleic acids, said promoter being selected from the promoter represented by the sequence SEQ ID NO: 5 (thl promoter) and the promoter represented by the sequence SEQ ID NO: 6. 
- -nukleinsku kiselinu opisanu u sekvenci SEQ ID NO: 3 ili nukleinsku kiselinu koja ima identičnost sekvence od najmanje 85 %, naročito 90 %, posebno 95 % sa sekvencom SEQ ID NO: 3, koja kodira za sekundarnu alkoholnu dehidrogenazu od CĆ. beijerinckiti, ekspresija navedenih nukleinskih kiselina kontrolirana je jednim konstitutivnim promotorom smještenim uzvodno od gore navedenih nukleinskih kiselina, pri čemu je spomenuti promotor odabran iz promotora opisanog u sekvenci SEQ ID NO: 5 (promotor thl) i promotora opisanog sekvencom SEQ ID NO: 6.
The pharmaceutical composition in form of emulsion or microemulsion according to claim 28, wherein said at least one lipophilic compound is selected from natural oils, such as almond oil, canola oil, castor oil, corn oil, cottonseed oil, olive oil, safflower oil, sesame oil, soybean oil and the like; fatty acid esters, such as isopropyl palmitate, isopropyl myristate, ethyl oleate and the like; fatty alcohols, such as myristic alcohol, oleyl alcohol and the like; fatty acids, such as myristic acid, oleyl acid, palmitic acid and the like, triglycerides, such as long and/or medium-chain triglycerides and the like; diglycerides and monoglycerides. 
Farmaceutski pripravak u obliku emulzije ili mikroemulzije prema zahtjevu 10, gdje se taj barem jedan lipofilni spoj odabire između prirodnih ulja, kao što su bademovo ulje, kanola ulje, ricinusovo ulje, kukuruzno ulje, pamučno ulje, maslinovo ulje, ulje šafranike, sezamovo ulje, sojino ulje; estera masnih kiselina, kao što su izopropil palmitat, izopropil miristat, etil oleat; masnih alkohola, kao što su miristinski alkohol, oleinski alkohol; masnih kiselina, kao što su miristinska kiselina, oleinska kiselina, palmitinska kiselina; triglicerida, kao što su dugolančani i/ili srednjelančani trigliceridi; diglicerida 1 monoglicerida. 12.
the transplanted material is a marginal organ; 
(ii) presađeni materijal je marginalni organ;
In a particular embodiment of the process, the aliphatic carboxylic acid employed in step (b) is 1:1 stearic acid:palmitic acid mixture, and the aliphatic carboxylic acid salt(s) employed in step (a) is a magnesium or calcium stearate. 
Postupak prema bilo kojem od zahtjeva 1 do 19, naznačen time da je alifatska karboksilna kiselina koja se koristi u koraku (b) smjesa u omjeru 1:1 stearinska kiselina: palmitinska kiselina, a sol(i) alifatske karboksilne kiseline koja se koristi u koraku (a) je magnezijev ili kalcijev stearat.
Compound 73 was obtained as a white solid from compound 72 by method A. 
Spoj 73 se dobiva kao bijela krutina iz spoja 72 pomoću postupka A.
A process according to claim 8, wherein the solvent is tetrahydrofuran, 2-methyl-tetrahydrofuran, tertbutylmethylether, di-isopropylether, di-ethylether, acetonitrile, ethylacetate, dichloromethane or toluene. 
Postupak prema zahtjevu 8, naznačen time da otapalo je tetrahidrofuran, 2-metil-tetrahidrofuran, tertbutilmetileter, di-izopropileter, di-etileter, acetonitril, etilacetat, diklorometan ili toluen.
recovering the expressed binding molecule. 
rekuperacija eksprimirane molekule za vezanje.
The method as claimed in any one of the preceding claims, wherein the liquid binder is a blank ink (11) comprising a liquid substance that is applied by a digital drop application head (30'). 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time što je tekuće vezivo bezbojna tinta (11) koja sadrži tekuću supstancu koja se primjenjuje pomoću digitalne aplikacijske glave (30).
contacting the complexes formed in step (iii) with a second member of a binding pair which is coupled to a detectable tag and 
stavljanja u kontakt kompleksa nastalih u koraku (iii) s drugim članom vežućeg para konjugiranim s fluorescentnim, luminescentnim ili enzimskim biljegom i
Once the cavity has overgrown, either at high or low sonic intensities, it can no longer absorb energy as efficiently. 
Kad je šupljina previše narasla uz visoki ili niski intenzitet, ne može dalje adsorbirati učinkovito energiju.
The pharmaceutical composition, antibody or functional fragment according to claim 38, wherein the cancer is lung cancer, breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, a melanoma, liver cancer, ovarian cancer, bladder cancer, stomach cancer, esophageal cancer, or kidney cancer. 
Farmaceutska kompozicija, antitijelo ili funkcionalni fragment prema patentnom zahtjevu 38, gdje rak je rak pluća, Tak dojke, rak prostate, rak gušterače, rak debelog crijeva, melanom, rak jetre, Tak jajnika, rak mjehura, rak trbuha, rak jednjaka, ili rak bubrega.
One example comprises use of the following compound: 
Broj objave europskog patenta:
The crystalline form of Febuxostat, designated Form F10, according to claim 1 characterized by a solid-state 13C NMR spectrum with signals at 112.7, 125.7, 132.4 and 168.3: ±0.2 ppm. The crystalline form of Febuxostat according to claim 1, further characterized by an X-ray powder diffraction pattern having peaks at 3.3°, 16.3°, 16.9°, 24.5° and 25.8°±0.2°20. The crystalline form of Febuxostat according to claim 1, wherein the crystalline form is substantially free of any other polymorphic forms of Febuxostat. 
Kristalni oblik febuksostata, označen kao Oblik F10, u skladu s patentnim zahtjevom 1, naznačen time što je za njega karakterističan uzorak difrakcije rendgenskih zraka na prahu, sa signalima na 6,7", 7,7%, 12,8%, 13,3% 1 20,0% + Kristalni oblik febuksostata označen kao Oblik F10, u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je za njega dodatno karakteristična difrakcija rendgenskih zraka na prahu sa signalima na 3,3%,
An isolated nucleic acid composition according to claim 4 wherein said first nucleic acid encodes SEQ ID NO:21 and said second nucleic acid encodes SEQ ID NO:22. 
Izolirano protutijelo prema zahtjevu 1 naznačeno time da teški lanac sadrži SEQ ID NO:21 1 lagani lanac sadrži SEQ ID NO:22.
A B2 agonist as defined in any one of claims 1 and 3 to 7, for simultaneous, concurrent, separate or sequential use in combination with an antagonist of M3 muscarinic receptors as defined in claim 1 or 2 for the treatment of a respiratory disease as defined in claim 11 or 12, while producing less heart side-effects than a therapeutically equivalent combination of tiotropium with the B2 agonist. A combination for use according to any one of claims 1 to 10 wherein the patient is suffering from a pre-existing heart condition or condition that would be aggravated by tachycardia. 
Antagonist M3 muskarinskih receptora, za uporabu u skladu sa zahtjevom 16, naznačen time, da pacijent pati od postojećeg stanje srca ili stanja koje će biti pogoršano tahikardijom B2 agonist kako je definirano u patentnom zahtjevu 1 ili 3, naznačen time, da je namijenjen za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u kombinaciji s antagonistom M3 muskarinskih receptora kako je definirano u patentnom zahtjevu 1 1li 2 za liječenje dišnih bolesti kao što je definirano u zahtjevu 7 ili 8.
The method of claim 1, wherein the compound is administered in the form of a gel. 
Spoj za uporabu prema zahtjevu 6, naznačen time da je navedeni spoj za davanje u obliku transdermalnog flastera, masti, losiona, kreme ili gela.
Separation can be carried out by forming a salt with a chiral acid such as (+) or (-) camphorsulphonic acid, separating the resulting diastereoisomers by fractional crystallisation to give a salt of a single enantiomer and then releasing the free base from the salt. 
Odijeljivanje se može provesti formiranjem soli s hiralnom kiselinom poput (+) ili (-) kamforsulfonske kiseline, odijeljivanjem rezultirajućih dijastereoizomera frakcijskom kristalizacijom da bi se dobila sol pojedinačnog enantiomera i zatim oslobađanjem slobodne baze 1z soli.
The method of any one of claims 1-3, wherein the pluripotent rat cell is characterized by expression of at least one pluripotency marker selected from the group consisting of Dnmt3L, Eras, Err-beta, Fbxo15, Fgf4, Gdf3, Klf4, Lef1, LIF receptor, Lin28, Nanog, Oct4, Sox15, Sox2, and Utf1. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1-3, naznačen time, da je pluripotentna stanica štakora karakterizirana ekspresijom najmanje jednog pluripotentnog markera izabranog iz skupine koju čine Dnmt3L, Eras, Err-beta, Fbxo15, Fgf4, Gdf3, KIfA4, Lef1, LIF receptora, Lin28, Nanog, Oct4, Sox15, Sox2 1 Utf1.